In a significant development for neurodegenerative disease treatment, BioPharma Dive reports that AC Immune has unveiled compelling evidence that its novel immunological strategy may fundamentally
An experimental cancer vaccine from the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy has delivered encouraging results in a phase
Chiesi Group has entered an exclusive licensing agreement with Aliada Therapeutics, a subsidiary of AbbVie, to develop therapies that can cross the blood-brain barrier (BBB)
As reported on Healio, new findings presented at The Liver Meeting highlight the potential of resmetirom (Rezdiffra, Madrigal Pharmaceuticals) in managing metabolic dysfunction-associated steatohepatitis (MASH)
Researchers at the University of Southampton have uncovered a hidden culprit in blood cancer, a unique sugar molecule that disguises aggressive lymphoma cells and renders
A new artificial intelligence model, popEVE, could accelerate diagnoses for rare, single-variant genetic diseases by scoring how likely each genetic change in a patient’s genome
University of Southampton researchers have identified a distinct subtype of diffuse large B‑cell lymphoma (DLBCL), termed “Mann-type DLBCL,” marked by a unique mannose sugar on
Light chain amyloidosis (AL) is a progressive and rare disease whereby abnormal plasma cells found in the blood and urine over-produce light chain proteins. These
The findings were recently published in Nature Immunology and reported by Precision Medicine suggesting that a factor called Interferon Regulatory Factor 4 (IRF4) takes responsibility
As reported on NPR, Tatiana Schlossberg, journalist and granddaughter of former U.S. President John F. Kennedy, has disclosed that she is battling a rare and
As reported on BioSpace, the U.S. Food and Drug Administration (FDA) has launched an investigation into reports of serious adverse events, including one fatality, associated
Three-year-old Oliver Chu has stunned clinicians after becoming the first person with Hunter syndrome (MPS II) to receive an experimental gene therapy and showing striking
Editor’s Note: Patient Worthy is pleased to share this article from our friends at Elephants & Tea, originally written by Cecily Liu. To see the
The United Leukodystrophy Foundation (ULF) is proud and excited to announce a partnership with Marc Nolan, a Chicago-based footwear brand, who is launching a new
The U.S. Food and Drug Administration (FDA) has approved Koselugo (selumetinib), an oral MEK inhibitor developed by Alexion, AstraZeneca Rare Disease, for adults with neurofibromatosis
Hundreds more patients in England with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) will gain earlier access to glofitamab (Columvi) after new guidance from
Vera Therapeutics has taken a major step toward transforming treatment for immunoglobulin A nephropathy (IgAN), submitting a Biologics License Application to the U.S. Food and
My journey started abruptly last year. It was a completely normal day—until it wasn’t. I’m an RN, and I slept most of the day before
New Study Finds Keytruda Combo Falls Short of Expectations in Unresectable-Non-Metastatic Hepatocellular Carcinoma bit.ly/4rG2hBH. Read now at PatientWorthy.com
#PatientWorthy #unresectable-Non-MetastaticHepatocellularCarcinoma #HCC
✨ The Holidays Can Be Hard – Daily Affirmations Matter ✨
For many living with chronic illness, the holiday season can feel overwhelming physically, mentally, and emotionally. Amid the hustle and bustle, remember to pause and give yourself grace.
💬 Try these affirmations today!
Small reminders can make a big difference. Take care of yourself—you deserve it. 💙
#chronicillness #HolidayWellness #dailyaffirmations #SelfCare #PatientWorthy
@FattyLiverFoundation
New Financial Help Available: Up to $4,200 in MASH Medication Assistance from PAN Foundation
Great news for patients living with MASH – significant financial help is now available to reduce your medication costs.
If you've been diagnosed with metabolic dysfunction-associated steatohepatitis (MASH), managing your condition shouldn't come with overwhelming financial stress. The PAN Foundation has just announced the opening of a new copay assistance program specifically designed to help patients like you afford essential MASH medications.
What is MASH?
MASH is a serious liver condition that occurs when fat builds up in your liver, causing inflammation and potential damage. You may have heard it referred to by its previous names – nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver disease.
You're not alone in this journey. According to the American Liver Foundation, more than 9 out of 15 adults in the U.S. are living with MASH. Unfortunately, experts project this number will increase by 63% by 2030, making MASH the leading cause of liver transplants today.
How Much Financial Help is Available?
The PAN Foundation's MASH copay assistance program offers substantial support:
• Initial grant: $2,100 to help cover out-of-pocket medication expenses
• Additional funding: If you need more help within the same 12-month period and funds are still available, you can apply for additional assistance
• Maximum annual benefit: Up to $4,200 total per year
This assistance is specifically designed to help reduce the financial burden of your MASH medications, allowing you to focus on your health and treatment rather than worrying about costs.
Why This Matters for Your Health
Managing MASH effectively often requires ongoing medication, and the cost can be a significant barrier to consistent treatment. When patients can't afford their medications, they may:
• Skip doses or stretch prescriptions
• Delay starting necessary treatments
• Experience worsening symptoms and complications
This financial assistance program removes those barriers, helping ensure you can access the medications your doctor prescribes without financial stress.
How to Take the Next Step
If you're living with MASH and struggling with medication costs, don't wait to explore this opportunity. Here's what you should do:
1. Visit the PAN Foundation website to learn about eligibility requirements
2. Gather your documentation including income information and insurance details
3. Complete the application online through their patient portal
4. Work with your healthcare team to ensure all necessary paperwork is submitted
Important Reminders
• Funding is limited and available on a first-come, first-served basis
• Applications are processed quickly once all required information is submitted
• You can reapply for additional funding within the same year if needed and funds remain available
• The program is designed specifically for MASH patients who meet eligibility criteria
Don't Let Cost Be a Barrier to Your Health
Living with MASH presents enough challenges without adding financial stress to the equation. This new PAN Foundation program represents a significant opportunity to reduce your medication costs and focus on what matters most – your health and well-being.
Take action today. Visit the PAN Foundation website to learn more about eligibility requirements and start your application. Your health is worth the investment, and this program is here to help make that investment more affordable.
Remember, you don't have to navigate MASH alone. In addition to this financial assistance, connect with patient support groups, work closely with your healthcare team, and explore other resources available to help you manage your condition effectively.
________________________________________
The PAN Foundation is a trusted nonprofit organization that has helped thousands of patients access the medications they need. This MASH copay assistance program represents their ongoing commitment to supporting patients with serious health conditions.
Wayne Eskridge
www.fattyliverfoundation.org/
Fatty Liver Foundation · 3938 E Shady Glen Ct, Boise, ID 83706, United States
This email was sent to [email protected]. To stop receiving emails, click here.
You can also keep up with Wayne Eskridge on Twitter or Facebook.
www.fattyliverfoundation.org
Fatty liver disease, NAFLD and NASH, steatohepatitis or cirrhosis, is epidemic and is a silent killer. About 30% of you have it. Millions will develop cirrhosis. Death from liver disease is increasing...
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
